MIRA INFORM REPORT

 

 

Report Date :

01.03.2013

 

IDENTIFICATION DETAILS

 

Name :

M.P.I. PHARMACEUTICA GMBH

 

 

Registered Office :

Ballindamm 8, D 20095 Hamburg

 

 

Country :

Germany

 

 

Financials (as on) :

31.12.2010

 

 

Date of Incorporation :

13.09.1985

 

 

Com. Reg. No.:

HRB 65217

 

 

Legal Form :

Private Limited Company

 

 

Line of Business :

Manufacturer of pharmaceutical preparations

 

 

No. of Employees :

23

 

RATING & COMMENTS

 

MIRA’s Rating :

Ba

 

RATING

STATUS

PROPOSED CREDIT LINE

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

Satisfactory

 

Status :

Satisfactory 

 

 

Payment Behaviour :

No  Complaints 

 

 

Litigation :

Clear 

NOTES:

Any query related to this report can be made on e-mail: infodept@mirainform.com while quoting report number, name and date.

 

ECGC Country Risk Classification List – June 30th, 2012

                                                   

Country Name

Previous Rating

(31.03.2012)

Current Rating

(30.06.2012)

Germany

A1

A1

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 


germany - ECONOMIC OVERVIEW

 

The German economy - the fifth largest economy in the world in PPP terms and Europe's largest - is a leading exporter of machinery, vehicles, chemicals, and household equipment and benefits from a highly skilled labor force. Like its Western European neighbors, Germany faces significant demographic challenges to sustained long-term growth. Low fertility rates and declining net immigration are increasing pressure on the country's social welfare system and necessitate structural reforms. Reforms launched by the government of Chancellor Gerhard SCHROEDER (1998-2005), deemed necessary to address chronically high unemployment and low average growth, contributed to strong growth in 2006 and 2007 and falling unemployment. These advances, as well as a government subsidized, reduced working hour scheme, help explain the relatively modest increase in unemployment during the 2008-09 recession - the deepest since World War II - and its decrease to 6.0% in 2011. GDP contracted 5.1% in 2009 but grew by 3.6% in 2010, and 2.7% in 2011. The recovery was attributable primarily to rebounding manufacturing orders and exports - increasingly outside the Euro Zone. Germany's central bank projects that GDP will grow 0.6% in 2012, a reflection of the worsening euro-zone financial crisis and the financial burden it places on Germany as well as falling demand for German exports. Domestic demand is therefore becoming a more significant driver of Germany's economic expansion. Stimulus and stabilization efforts initiated in 2008 and 2009 and tax cuts introduced in Chancellor Angela MERKEL's second term increased Germany's budget deficit to 3.3% in 2010, but slower spending and higher tax revenues reduce the deficit to 1.7% in 2011, below the EU's 3% limit. A constitutional amendment approved in 2009 limits the federal government to structural deficits of no more than 0.35% of GDP per annum as of 2016. Following the March 2011 Fukushima nuclear disaster, Chancellor Angela Merkel announced in May 2011 that eight of the country's 17 nuclear reactors would be shut down immediately and the remaining plants would close by 2022. Germany hopes to replace nuclear power with renewable energy. Before the shutdown of the eight reactors, Germany relied on nuclear power for 23% of its energy and 46% of its base-load electrical production.

 

Source : CIA

 

 


Company name

 

M.P.I. Pharmaceutica GmbH

 

 

Company Address 

 

Ballindamm 8

D 20095 Hamburg

Telephone:        040/303724-0

Telefax:             040/303724-20

Homepage:        www.mpi-pharma.com

E-mail:              info@mpi-pharma.de

Company Status:      active

 

 

VAT no

 

DE118671386

 

 

CONCLUSION

 

Business relations are permissible.

 

 

Synthesis

 

LEGAL FORM               Private limited company

Date of foundation:         13.09.1985

Shareholders'

agreement:                    13.09.1985

Registered on:               26.08.1997

Commercial Register:     Local court 20355 Hamburg

under:                                       HRB 65217

Share capital:                 EUR            130,000.00

 

 

Shareholder

 

Franz Wilhelm Gerhardy

Dörpfeldstieg 1

D 22609 Hamburg

born: 12.05.1941

Share:             EUR            130,000.00

 

 

Manager

 

Franz Wilhelm Gerhardy

Dörpfeldstieg 1

D 22609 Hamburg

having sole power of representation

born: 12.05.1941

Profession: Businessman

Marital status: married

 

 

Proxy

 

Christoph Frese

D 20095 Hamburg

authorized to jointly represent the company

born: 03.03.1938

Profession: Businessman

Marital status: unknown

 

Further functions/participations of Franz Wilhelm Gerhardy

(Manager)

 

Shareholder:

                      ALPHACHEM Im- + Exportgesellschaft mbH

                      Ballindamm 8

                      D 20095 Hamburg

                      Legal form: Private limited company

                      Share capital:     EUR             30,677.51

                      Share:             EUR             30,677.51

                      Registered

                      on:         22.11.1984

                      Reg. data:  20355 Hamburg, HRB 33448

 Manager:

                      IMEDIKA Chemie GmbH

                      Ballindamm 8

                      D 20095 Hamburg

                      Legal form: Private limited company

                      Share capital:     EUR             25,000.00

                      Registered

                      on:         20.12.2002

                      Reg. data:  20355 Hamburg, HRB 85890

 Manager:

                      ALPHACHEM Im- + Exportgesellschaft mbH

                      Ballindamm 8

                      D 20095 Hamburg

                      Legal form: Private limited company

                      Share capital:     EUR             30,677.51

                      Registered

                      on:         22.11.1984

                      Reg. data:  20355 Hamburg, HRB 33448

 

 

COMPANY HISTORY

 

 07.09.1998 - 02.10.1998  M.P.I. Pharmaceutica GmbH

                          Spohrstr. 2

                          D 22083 Hamburg

                          Private limited company

 

 

BUSINESS ACTIVITIES

 

Sectors

21200   Manufacture of pharmaceutical preparations

46461   Wholesale of pharmaceutical goods

 

 

FINANCIAL INFORMATION

 

Payment experience:     within agreed terms

 

Negative information:      We have no negative information at hand.

 

Balance sheet year:       2010

 

 

REAL ESTATE

 

 Type of ownership:        Tenant

 Address                       Ballindamm 8

                                    D 20095 Hamburg

 

 Land register documents were not available.

 

 

BANKERS

 

DEUTSCHE BANK, HAMBURG

Sort. code: 20070000, Account no.: 6426605, BIC: DEUTDEHHXXX

 


HAMBURGER SPARKASSE, HAMBURG

Sort. code: 20050550, Account no.: 1280117357, BIC: HASPDEHHXXX

 

UNICREDIT BANK - HYPOVEREINSBANK, HAMBURG

Sort. code: 20030000, Account no.: 1160126, BIC: HYVEDEMM300

 

 

FINANCIAL FIGURES

 

Gross profit or loss:2011               EUR          5,000,000.00

2012               EUR          5,000,000.00

further business figures:

Equipment:                              EUR             28,076.00

Ac/ts receivable:                       EUR          6,317,628.00

Liabilities:                            EUR          4,203,539.00

Employees:                                                     23

 

 

BALANCE SHEETS

 

 Balance sheet ratios 01.01.2010 - 31.12.2010

 Equity ratio [%]:                 42.65

 Liquidity ratio:                   1.58

 Return on total capital [%]:       5.56

 

 Balance sheet ratios 01.01.2009 - 31.12.2009

 Equity ratio [%]:                 45.81

 Liquidity ratio:                   1.87

 Return on total capital [%]:       9.77

 

 Balance sheet ratios 01.01.2008 - 31.12.2008

 Equity ratio [%]:                 27.55

 Liquidity ratio:                   1.21

 Return on total capital [%]:       4.62

 

 Balance sheet ratios 01.01.2007 - 31.12.2007

 Equity ratio [%]:                 19.14

 Liquidity ratio:                   1.12

 Return on total capital [%]:       3.00

 

Equity ratio

The equity ratio indicates the portion of the equity as compared

to the total capital. The higher the equity ratio, the better the

economic stability (solvency) and thus the financial autonomy of

a company.

 

Liquidity ratio

The liquidity ratio shows the proportion between adjusted

receivables and net liabilities. The higher the ratio, the lower

the company's financial dependancy from external creditors.

 

Return on total capital

The return on total capital shows the efficiency and return on

the total capital employed in the company. The higher the return

on total capital, the more economically does the company work

with the invested capital.

 

Type of balance

 sheet:               Company balance sheet

 

 Financial year:      01.01.2010 - 31.12.2010

 

 ASSETS                                  EUR          7,309,669.01

  Fixed assets                           EUR             28,076.00

   Tangible assets                       EUR             28,076.00

    Other tangible assets / fixtures and

    fittings                             EUR             28,076.00

  Current assets                         EUR          7,275,961.88

   Stocks                                EUR            936,003.36

   Accounts receivable                   EUR          6,317,628.39

    Trade debtors                        EUR          6,180,373.85

    Other debtors and assets             EUR            137,254.54

   Liquid means                          EUR             22,330.13

  Remaining other assets                 EUR              5,631.13

   Accruals (assets)                     EUR              5,631.13

 

 LIABILITIES                             EUR          7,309,669.01

  Shareholders' equity                   EUR          2,932,289.35

   Capital                               EUR            128,334.26

    Subscribed capital (share capital)   EUR            128,334.26

   Balance sheet profit/loss (+/-)       EUR          2,803,955.09

    Balance sheet profit / loss          EUR          2,803,955.09

  Provisions                             EUR            173,840.58

  Liabilities                            EUR          4,203,539.08

   Financial debts                       EUR          2,233,285.41

    Liabilities due to banks             EUR          2,233,285.41

   Other liabilities                     EUR          1,970,253.67

    Trade creditors (for IAS incl. bills

    of exchange)                         EUR          1,745,409.76

    Unspecified other liabilities        EUR            224,843.91

 

 PROFIT AND LOSS ACCOUNT (cost-summary method) according to Comm.

 Code (HGB)

  Gross result (+/-)                     EUR          4,977,691.60

  Staff expenses                         EUR            609,000.39

   Wages and salaries                    EUR            526,311.87

   Social security contributions and

   expenses for pension plans and

   benefits                              EUR             82,688.52

  Total depreciation                     EUR             19,117.41

   Depreciation on tangible / intangible

   asssets (incl. start-up and exp. of

   bus.                                  EUR             19,117.41

  Other operating expenses               EUR          3,670,142.83

  Operating result from continuing

  operations                             EUR            679,430.97

  Interest result (+/-)                  EUR            -86,015.11

   Interest and similar income           EUR                477.40

   Interest and similar expenses         EUR             86,492.51

  Financial result (+/-)                 EUR            -86,015.11

  Result from ordinary operations (+/-)  EUR            593,415.86

  Extraordinary expenses                 EUR             29,909.00

  Extraordinary result (+/-)             EUR            -29,909.00

  Income tax / refund of income tax (+/-)EUR           -186,262.12

  Other taxes / refund of taxes          EUR               -617.00

  Tax (+/-)                              EUR           -186,879.12

  Annual surplus / annual deficit        EUR            376,627.74

 

 Type of balance

 sheet:               Company balance sheet

 

 Financial year:      01.01.2009 - 31.12.2009

 

 ASSETS                                  EUR          6,124,289.88

  Fixed assets                           EUR            212,438.00

   Tangible assets                       EUR             42,438.00

    Other tangible assets / fixtures and

    fittings                             EUR             42,438.00

   Financial assets                      EUR            170,000.00

    Other / unspecified financial assets EUR            170,000.00

  Current assets                         EUR          5,909,733.20

   Stocks                                EUR            686,866.19

   Accounts receivable                   EUR          4,908,915.03

    Other debtors and assets             EUR          4,908,915.03

   Liquid means                          EUR            313,951.98

  Remaining other assets                 EUR              2,118.68

   Accruals (assets)                     EUR              2,118.68

 

 LIABILITIES                             EUR          6,124,289.88

  Shareholders' equity                   EUR          2,555,661.61

   Capital                               EUR            128,334.26

    Subscribed capital (share capital)   EUR            128,334.26

   Balance sheet profit/loss (+/-)       EUR          2,427,327.35

    Balance sheet profit / loss          EUR          2,427,327.35

  Provisions                             EUR            383,131.82

  Liabilities                            EUR          3,185,496.45

   Financial debts                       EUR          1,525,877.73

    Liabilities due to banks             EUR          1,525,877.73

   Other liabilities                     EUR          1,659,618.72

    Unspecified other liabilities        EUR          1,659,618.72

 

 PROFIT AND LOSS ACCOUNT (cost-summary method) according to Comm.

 Code (HGB)

  Gross result (+/-)                     EUR          4,845,696.55

  Staff expenses                         EUR            653,272.89

   Wages and salaries                    EUR            565,646.14

   Social security contributions and

   expenses for pension plans and

   benefits                              EUR             87,626.75

  Total depreciation                     EUR             12,377.43

   Depreciation on tangible / intangible

   asssets (incl. start-up and exp. of

   bus.                                  EUR             12,377.43

  Other operating expenses               EUR          3,176,812.75

  Operating result from continuing

  operations                             EUR          1,003,233.48

  Interest result (+/-)                  EUR           -111,012.01

   Interest and similar income           EUR              4,890.42

   Interest and similar expenses         EUR            115,902.43

  Financial result (+/-)                 EUR           -111,012.01

  Result from ordinary operations (+/-)  EUR            892,221.47

  Income tax / refund of income tax (+/-)EUR           -293,183.88

  Other taxes / refund of taxes          EUR               -465.00

  Tax (+/-)                              EUR           -293,648.88

  Annual surplus / annual deficit        EUR            598,572.59

 

 

 

 

 

 

 

 


FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs.53.77

UK Pound

1

Rs.81.57

Euro

1

Rs.70.68

 

INFORMATION DETAILS

 

Report Prepared by :

MNL

 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

----

NB

New Business

----

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                 Payment record (10%)

Credit history (10%)                    Market trend (10%)                                Operational size (10%)

 

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.